All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

GLP-1 weight regain after stopping: what the data shows

Lasting Weight Loss

TikTok creator

22.2K viewsWatch on TikTok→

Quick answer

Weight regain after GLP-1 receptor agonist discontinuation is biologically driven by hormonal adaptations including reduced leptin and elevated ghrelin, which persist well beyond the period of active medication use. Lifestyle interventions including low-carbohydrate diets and intermittent fasting show evidence for improving insulin sensitivity and reducing inflammatory markers, but have not been demonstrated in controlled trials to durably alter defended body weight biology in the way the creator implies. AOD 9604 has no FDA approval and no completed Phase III human trials supporting its use in weight management or as a GLP-1 adjunct.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @drjonesdc actually say?

The creator, who identifies as a DC (doctor of chiropractic), claims that weight creeping back after GLP-1 therapy can be stopped by improving "metabolic health" through low-carb eating for three to six months combined with extended fasting. The logic: become more insulin sensitive, reduce inflammation, and you lower your body's weight "set point" permanently. He also mentions AOD 9604, a peptide, as something that makes fasting easier alongside GLP-1 medications.

The core pitch is that strategic longer fasting periods on non-fasting days will make weight maintenance "a breeze." That's a strong promise. Let's see what the evidence actually supports.

Does the science back this up?

Partially, yes, but with important caveats. The evidence for low-carbohydrate diets improving insulin sensitivity is real. A 2022 trial by Ebbeling et al. in the American Journal of Clinical Nutrition found that low-carb diets increased energy expenditure and improved metabolic markers in adults with overweight. That part holds up.

The set point language is where things get slippery. "Set point" is a popular concept, but the more accurate term researchers use is "defended body weight," which reflects biological adaptations including changes in leptin, ghrelin, and thyroid hormones after weight loss. A landmark 2011 study by Sumithran et al. in the New England Journal of Medicine showed these hormonal adaptations persist for at least a year after weight loss, driving hunger and regain. The claim that fasting can permanently "lower" this defended weight is speculative. There is no robust long-term human trial proving extended fasting resets set point biology in a durable way.

Intermittent fasting does show metabolic benefits in short-term trials. A 2020 review by de Cabo and Mattson in the New England Journal of Medicine found improvements in insulin sensitivity, blood pressure, and inflammation markers. But "breeze" is doing a lot of heavy lifting here.

What did they get wrong (or right)?

Credit where it is due: the general direction of the advice, eat less ultra-processed food, reduce carbohydrate load, incorporate fasting, is supported by evidence for metabolic improvement. These are not fringe ideas.

What is more problematic is the AOD 9604 mention. AOD 9604 is a synthetic peptide fragment derived from human growth hormone. The FDA has not approved it for any indication. It has not completed Phase III clinical trials for weight management. The creator slips it in casually, implying it works synergistically with GLP-1s to make fasting easier. There is no peer-reviewed clinical evidence supporting that claim in humans. Recommending unregulated peptides to a 22,000-person audience without that context is irresponsible, regardless of how it was framed.

The "set point" framing is also oversimplified to the point of being misleading. Suggesting that dietary changes alone can permanently eliminate biological weight defense mechanisms sets up patients for guilt when regain happens anyway, which data shows it often does after GLP-1 discontinuation regardless of lifestyle habits.

What should you actually know?

Weight regain after GLP-1 discontinuation is not a personal failure, it is a documented pharmacological reality. The 2022 STEP 4 trial published in JAMA showed that participants who stopped semaglutide regained two-thirds of their lost weight within one year, even with continued lifestyle intervention. The medication is doing significant biological work that diet alone cannot fully replicate once it is gone.

That does not mean lifestyle changes are useless. Resistance training, specifically preserving muscle mass during GLP-1 therapy, is one of the strongest evidence-backed strategies for improving long-term metabolic outcomes and slowing regain. A 2023 paper by Lundgren et al. in Obesity emphasized that muscle mass preservation during GLP-1 treatment substantially affects resting metabolic rate after cessation.

If you are experiencing weight creep after GLP-1 therapy, the conversation should start with your prescribing clinician, not a TikTok algorithm. Dose adjustments, medication switches, or structured lifestyle programs supervised by a registered dietitian all carry more evidence than a fasting protocol promoted by a chiropractor on social media.

Bottom line: worth watching or worth skipping?

The lifestyle direction is reasonable. The set point language is oversimplified. The AOD 9604 mention is a red flag that should make anyone pause. A chiropractor coaching "thousands of patients on GLP-1s every single day" is also a credential claim worth scrutinizing. Chiropractors are not licensed to prescribe medications in any U.S. state. How that coaching relationship works legally is a question this video does not answer. Take the general dietary advice with some merit, and leave the peptide recommendations alone until there is actual clinical evidence to support them.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For GLP-1 weight regain after stopping: what the data shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

Use the health tools and supporting evidence to prepare questions for your clinician.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Claim verdict

The useful answer behind this video

Claim being checked

Weight regain after GLP-1 receptor agonist discontinuation is biologically driven by hormonal adaptations including reduced leptin and elevated ghrelin, which persist well beyond the period of active medication use.

FormBlends verdict

Weight regain after GLP-1 receptor agonist discontinuation is biologically driven by hormonal adaptations including reduced leptin and elevated ghrelin, which persist well beyond the period of active medication use. Lifestyle interventions including low-carbohydrate diets and intermittent fasting show evidence for improving insulin sensitivity and reducing inflammatory markers, but have not been demonstrated in controlled trials to durably alter defended body weight biology in the way the creator implies. AOD 9604 has no FDA approval and no completed Phase III human trials supporting its use in weight management or as a GLP-1 adjunct.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Weight regain after GLP-1 receptor agonist discontinuation is biologically driven by hormonal adaptations including reduced leptin and elevated ghrelin, which persist well beyond the period of active medication use. Lifestyle interventions including low-carbohydrate diets and intermittent fasting show evidence for improving insulin sensitivity and reducing inflammatory markers, but have not been demonstrated in controlled trials to durably alter defended body weight biology in the way the creator implies. AOD 9604 has no FDA approval and no completed Phase III human trials supporting its use in weight management or as a GLP-1 adjunct.
  • The 2022 STEP 4 trial (JAMA) found that people who stopped semaglutide regained about two-thirds of their lost weight within one year, even with ongoing lifestyle support.
  • Low-carbohydrate diets do improve insulin sensitivity in controlled settings, but long-term adherence rates are low and results vary considerably between individuals.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • The 2022 STEP 4 trial (JAMA) found that people who stopped semaglutide regained about two-thirds of their lost weight within one year, even with ongoing lifestyle support.
  • Low-carbohydrate diets do improve insulin sensitivity in controlled settings, but long-term adherence rates are low and results vary considerably between individuals.
  • AOD 9604 is an unapproved synthetic peptide with no completed Phase III human trials. There is no clinical evidence supporting its use as a GLP-1 adjunct.
  • The biological concept of a "defended body weight" is real, driven by hormonal changes in leptin and ghrelin, but evidence that fasting can permanently reset this biology in humans is not established.
  • Resistance training and muscle mass preservation during GLP-1 therapy have stronger evidence for improving long-term metabolic outcomes than fasting alone (Lundgren et al., 2023, Obesity).
  • Chiropractors are not licensed to prescribe medications in any U.S. state. Anyone describing themselves as coaching patients on GLP-1 medications warrants scrutiny about the nature of that clinical relationship.
  • Intermittent fasting shows real short-term benefits for insulin sensitivity and inflammation markers (de Cabo and Mattson, 2020, NEJM), but calling maintenance a "breeze" overstates what the evidence actually shows.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Lasting Weight Loss · TikTok creator

22.2K views on this video

Replying to @Mar Lizárraga Weight’s creeping back after GLP-1? Watch this NOW. #fyp #glp1 #foryoupage #glp1community #tirzepatide

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Lasting Weight Loss, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.